论文部分内容阅读
[目的]观察阿德福韦酯胶囊联合复方鳖甲软肝片治疗慢性乙型肝炎和代偿期肝硬化患者抗肝纤维化临床疗效。[方法]125例慢性乙型肝炎后肝纤维化患者随机分为阿德福韦酯胶囊与复方鳖甲软肝片联合治疗(治疗)组及阿德福韦酯胶囊(对照)组,每月查肝功能等生化指标,每3个月检测HBVM、HBV DNA,分别于治疗前和治疗12个月后放射免疫法各检测1次血清肝纤维化指标。[结果]12个月后治疗组及对照组肝功能均明显恢复,2组比较差异无统计学意义;2组HBeAg阴转率、HbeAg/HBeAb血清转换率、HBV DNA阴转率差异均无统计学意义(均P>0.05),治疗组肝纤维化程度改善更明显(P<0.05)。[结论]阿德福韦酯胶囊与复方鳖甲软肝片联合治疗在抗纤维化程度方面优于单用阿德福韦酯胶囊。
[Objective] To observe the curative effect of adefovir dipivoxil capsule and compound Biejia Ruangan Tablet on anti-hepatic fibrosis in patients with chronic hepatitis B and decompensated cirrhosis. [Method] A total of 125 patients with posthepatitic cirrhosis with chronic hepatitis B were randomly divided into adefovir dipivoxil capsules and Fufang Biejia Ruangan Tablet combined treatment group and adefovir dipivoxil capsule (control group) Check liver function and other biochemical indicators, HBVM every 3 months, HBV DNA, respectively, before and 12 months after treatment by radioimmunoassay 1 serum liver fibrosis indicators. [Results] After 12 months, the liver function of the treatment group and the control group recovered obviously. There was no significant difference between the two groups. There was no statistical difference in the negative conversion rate of HBeAg, HbeAg / HBeAb seroconversion rate and HBV DNA negative conversion rate Significance (both P> 0.05), the treatment group, the degree of improvement of liver fibrosis more significant (P <0.05). [Conclusion] Combination of adefovir dipivoxil capsule and Fufang Biejia Ruangan Pian is better than adefovir dipivoxil alone in the degree of anti-fibrosis.